High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker

被引：3

作者：

Liu, Shiqin ^{[1
]}

Hawley, Sarah J. ^{[2
]}

Kunder, Christian A. ^{[3
]}

Hsu, En-Chi ^{[4
]}

Shen, Michelle ^{[1
]}

Westphalen, Lennart ^{[1
]}

Auman, Heidi ^{[2
]}

Newcomb, Lisa F. ^{[5
]}

Lin, Daniel W. ^{[5
]}

Nelson, Peter S. ^{[6
]}

Feng, Ziding ^{[7
]}

Tretiakova, Maria S. ^{[8
]}

True, Lawrence D. ^{[8
]}

Vakar-Lopez, Funda ^{[8
]}

Carroll, Peter R. ^{[9
]}

Simko, Jeffry ^{[9
]}

Gleave, Martin E. ^{[10
]}

Troyer, Dean A. ^{[11
]}

Mckenney, Jesse K. ^{[12
]}

Brooks, James D. ^{[13
]}

Liss, Michael A. ^{[14
]}

Stoyanova, Tanya ^{[1
,15
]}

机构：

[1] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA

[2] Canary Fdn, Woodside, CA USA

[3] Stanford Univ, Dept Pathol, Palo Alto, CA USA

[4] Stanford Univ, Dept Radiol, Palo Alto, CA USA

[5] Univ Washington, Dept Urol, Seattle, WA USA

[6] Fred Hutchinson Canc Ctr, Div Human Biol, Seattle, WA USA

[7] Fred Hutchinson Canc Ctr, Program Biostat & Biomath, Div Publ Hlth Sci, Seattle, WA USA

[8] Univ Washington, Dept Lab Med & Pathol, Med Ctr, Seattle, WA USA

[9] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA

[10] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada

[11] Eastern Virginia Med Sch, Dept Pathol, Norfolk, VA USA

[12] Cleveland Clin, Dept Anat Pathol, Cleveland, OH USA

[13] Stanford Univ, Dept Urol, Palo Alto, CA USA

[14] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA

[15] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA

来源：

SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期

基金：

美国国家卫生研究院;

关键词：

ANTIBODY-DRUG CONJUGATE; RADICAL PROSTATECTOMY; SACITUZUMAB GOVITECAN; PREDICTION; DIAGNOSIS;

D O I：

10.1038/s41598-023-50215-z

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences clinical decision-making between treatment and active surveillance. The development of novel predictive biomarkers will help with risk stratification, and clinical decision-making, leading to a decrease in over or under-treatment of patients with prostate cancer. Here, we report that Trop2 is a prognostic tissue biomarker for clinically significant prostate cancer by utilizing the Canary Prostate Cancer Tissue Microarray (CPCTA) cohort composed of over 1100 patients from a multi-institutional study. We demonstrate that elevated Trop2 expression is correlated with worse clinical features including Gleason score, age, and pre-operative PSA levels. More importantly, we demonstrate that elevated Trop2 expression at radical prostatectomy predicts worse overall survival in men undergoing radical prostatectomy. Additionally, we detect shed Trop2 in urine from men with clinically significant prostate cancer. Our study identifies Trop2 as a novel tissue prognostic biomarker and a candidate non-invasive marker for prostate cancer.

引用

页数：8

共 39 条

[1] MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis [J].

Ahdoot, Michael ;

Wilbur, Andrew R. ;

Reese, Sarah E. ;

Lebastchi, Amir H. ;

Mehralivand, Sherif ;

Gomella, Patrick T. ;

Bloom, Jonathan ;

Gurram, Sandeep ;

Siddiqui, Minhaj ;

Pinsky, Paul ;

Parnes, Howard ;

Linehan, W. Marston ;

Merino, Maria ;

Choyke, Peter L. ;

Shih, Joanna H. ;

Turkbey, Baris ;

Wood, Bradford J. ;

Pinto, Peter A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10) :917-928

[2] The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches [J].

Alarcon-Zendejas, Ana Paula ;

Scavuzzo, Anna ;

Jimenez-Rios, Miguel A. ;

Alvarez-Gomez, Rosa M. ;

Montiel-Manriquez, Rogelio ;

Castro-Hernandez, Clementina ;

Jimenez-Davila, Miguel A. ;

Perez-Montiel, Delia ;

Gonzalez-Barrios, Rodrigo ;

Jimenez-Trejo, Francisco ;

Arriaga-Canon, Cristian ;

Herrera, Luis A. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) :431-443

[3] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [J].

Bardia, A. ;

Messersmith, W. A. ;

Kio, E. A. ;

Berlin, J. D. ;

Vahdat, L. ;

Masters, G. A. ;

Moroose, R. ;

Santin, A. D. ;

Kalinsky, K. ;

Picozzi, V ;

O'Shaughnessy, J. ;

Gray, J. E. ;

Komiya, T. ;

Lang, J. M. ;

Chang, J. C. ;

Starodub, A. ;

Goldenberg, D. M. ;

Sharkey, R. M. ;

Maliakal, P. ;

Hong, Q. ;

Wegener, W. A. ;

Goswami, T. ;

Ocean, A. J. .

ANNALS OF ONCOLOGY, 2021, 32 (06) :746-756

[4] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[5] Serum and urine biomarkers for detecting clinically significant prostate cancer [J].

Becerra, Maria F. ;

Atluri, Venkatasai S. ;

Bhattu, Amit S. ;

Punnen, Sanoj .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) :686-690

[6] Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients [J].

Bignotti, Eliana ;

Todeschini, Paola ;

Calza, Stefano ;

Falchetti, Marcella ;

Ravanini, Maria ;

Tassi, Renata A. ;

Ravaggi, Antonella ;

Bandiera, Elisabetta ;

Romani, Chiara ;

Zanotti, Laura ;

Tognon, Germana ;

Odicino, Franco E. ;

Facchetti, Fabio ;

Pecorelli, Sergio ;

Santin, Alessandro D. .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (05) :944-953

[7] High-risk prostate cancer-classification and therapy [J].

Chang, Albert J. ;

Autio, Karen A. ;

Roach, Mack, III ;

Scher, Howard I. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (06) :308-323

[8] The CAPRA-S Score A Straightforward Tool for Improved Prediction of Outcomes After Radical Prostatectomy [J].

Cooperberg, Matthew R. ;

Hilton, Joan F. ;

Carroll, Peter R. .

CANCER, 2011, 117 (22) :5039-5046

[9] Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer [J].

Cooperberg, Matthew R. ;

Broering, Jeanette M. ;

Carroll, Peter R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1117-1123

[10] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].

D'Amico, AV ;

Whittington, R ;

Malkowicz, SB ;

Schultz, D ;

Blank, K ;

Broderick, GA ;

Tomaszewski, JE ;

Renshaw, AA ;

Kaplan, I ;

Beard, CJ ;

Wein, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974

← 1 2 3 4 →